Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft
Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending on the progress of the research, Takeda could pay its new partner more than $900 million.
Source: medcitynews.com